maintain market perform rate share
follow review result outlook
report result yesterday updat
key initi non-gaap ep ahead consensu
yoy driven yoy increas total product
sale includ intern volum growth reduc
share count follow dutch auction base
result revis outlook revenu guidanc increas
 ep guidanc increas
prior guidanc
increas ep estim
previou quarter establish product revenu declin
highlight prolia sale vs consensu
yoy market penetr increas
invest prolia kyproli sale vs
consensu reflect yoy growth driven increas use ex-u
stabl use xgeva sale ahead
consensu reflect roughli buy-in follow
label expans see market opportun
myeloma patient could benefit xgeva repatha
sale ahead consensu repres
higher unit demand estim singl digit penetr
estim million high risk patient compani
remain negoti sever payer improv access
return reduct drug cost sensipar beat consensu
vs due switch reimburs part
part believ led dialysi clinic purchas
addit suppli avoid dose interrupt
launch amgn first class migrain drug aimovig
amgn first biosimilar amjevita humira identifi key
new product opportun hire train sale team
ahead may pdufa aimovig expect
launch amjevita intern market amgn biosimilar
kanjinti biosimilar herceptin bsufa date
also note growth opportun approv xgeva myeloma
neulasta onpro europ
term earlier stage pipelin opportun highlight
program featur recent american associ cancer
research meet includ two program directli
compar amgn bispecif cell engag bite format
chimer antigen receptor car-t cell therapi car-t
product kite/gild collabor first two
target small cell lung cancer acut myeloid
leukemia respect continu next page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
non-gaap ep exclud stock-bas compens reflect adjust
compani prioriti stock list
compani data secur llc estim reuter
continu expect data bcma bite bite
hle bite bcma back develop
outsid oncolog highlight mutein abl expand regulatori
cell effector cell evalu autoimmun diseas includ rheumatoid
arthriti system lupu erythematosu chronic graft versu host diseas
price target nc
arriv price target appli multipl ep estim
risk includ greater expect eros base biolog busi competit kyproli
gener velcad emerg myeloma treatment failur gain approv proprietari
expens price-to-earnings basi rel growth view face signific headwind
biosimilar brand competit legaci franchis
larg cap global commercial-stag biotechnolog compani discov develop biolog
small molecul drug specialti physician discoveri pipelin led compani
broaden focu oncolog immune-medi inflammatori diseas renal diseas includ
bone diseas cardiovascular neurolog diseas addit taken lead posit
develop biosimilar compani face near-term biosimilar competit legaci
